C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annua
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annua（摘要待生成）
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy（摘要待生成）
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference（摘要待生成）
Satya Nadella's Microsoft Now Has a $678 Billion Sales Backlog, Up 84% Year Over Year, After Azure Topped $100 Billion in Annual Revenue. Does That Growth Justify the Stock's Forward P/E of 25?
Satya Nadella's Microsoft Now Has a $678 Billion Sales Backlog, Up 84% Year Over Year, After Azure Topped $100 Billion in Annual Revenue. Does That Growth Justify the Stock's Forward P/E of 25?（摘要待生成）
Xunce Technology Launches TokenCloud, Redefining the Value of Computing Power Through Full-Chain AI Infrastructure and Securing a Leading Position in the Token Economy Era
Xunce Technology Launches TokenCloud, Redefining the Value of Computing Power Through Full-Chain AI Infrastructure and Securing a Leading Position in the Token Economy Era（摘要待生成）